Self-government HPV vaccination programmes in Poland, 2009–2016
More details
Hide details
Medical University, Warsaw, Poland
Institute of Rural Heath, Lublin, Poland
Anna Augustynowicz   

Medical University, Warsaw, Poland
Cervical cancer is the fourth neoplasm in women with respect to incidence. In Poland, both cervical cancer incidence and corresponding mortality are gradually decreasing. Despite these improvements, the epidemiological situation significantly deviates from European standards. Poland has one of Europe’s lowest five-year survival rates at 54.1% for patients diagnosed in 2000–2002, compared to the European mean value of 62.1%.

The aim of this study is to present health policy programmes related to HPV vaccinations run by local self-government units in 2009–2016.

Material and methods:
The research is based on analysis of already existing data developed by provincial governors and annual information reviews on health-policy programmes implemented by local self-government units presented to the Ministry of Health. All the programmes that included HPV vaccinations have been subjected to analysis.

In 2009–2016, local government units implemented a total of 1,204 health policy programmes that covered HPV vaccinations. Under these programmes, 2.05% of girls aged 10–14 were vaccinated. Percentage-wise, these were communes that contributed the most financially to the HPV vaccination programmes, whereas the counties the least.

Local self-government’s programmes covering HPV vaccinations conform with the trends outlined in strategic documents on fighting neoplastic diseases. It is possible that the availability of HPV vaccination was limited for girls living in rural communes. Differences in the number of programmes, number of vaccinated girls and the financial outlays allocated for the implementation of HPV vaccination programmes in particular provinces, may be determined by the epidemiological situation in a given region, measured by the incidence rate of cervical cancer.

Stewart BW. Wild CP. World Cancer Report 2014. International Agency for Research on Cancer, Lyon 2014.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; access 8 march 2019.
Wojciechowska U, Didkowska J, Zatoński W. [Malicious neoplasms in Poland in 2010, Ministry of Health], Warsaw 2012. Polish.
Wojciechowska U, Czaderny K, Ciuba A, Olasek P, Didkowska J. [Malicious neoplasms in Poland in 2016], Ministry of Health, Warsaw 2018. Polish.
Didkowska J, Wojciechowska U, Zatoński W. [Incidence and mortality rate forecasts for malicious neoplasms in Poland until 2025], Maria Skłodowska-Curie Institute of Oncology, Warsaw 2009. Polish.
Wojciechowska U, Didkowska J, Zatoński W. [Survival rates in malicious neoplasm patients diagnosed in Poland in 2000–2002], Maria Skłodowska-Curie Institute of Oncology, Warsaw 2009. Polish.
European Cancer Observatory,; access: 10 march 2019.
Act of 1 July 2005 on establishment of a long-term programme: National Programme for Fighting Cancer (Journal of Laws no. 143, item 1200, as amended).
Resolution of the Council of Ministers no. 208 of 3 November 2015 on establishment of a long-term programme for 2016–2024 entitled: National Programme for Fighting Cancer, M.P. of 2015, item 1165.
Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obst Gynaecol. 2018; 47: 42–58.
European Centre for Disease Prevention and Control. Recommended immunisations for human papillomavirus infection. http://vaccine; access 13 march 2019.
World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. WHO, Geneva 2014: 99–115.
World Health Organization, Human papillomavirus vaccines: WHO position paper, May 2017. Weekly Epidemiological Record, 2017; 92 (19): 241–268.
Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, Newcomer SR, Tolsma D, Markowitz LE. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. Am J Epidemiol. 2018; 187(2): 298–305.
Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, Pollock KG. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap. J Epidemiol Comm Health. 2017; 71: 954–960.
Navarro-Illana E, López-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Vaccine 2017; 35(25): 3342–3346.
Heard I, Tondeur L, Arowas L, Demazoin M, Falguières M, Parent Du Chatelet I. pour le groupe CHlaHPV, Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France. J Infect Dis. 2017; 215: 757–763.
Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Australia. 2016; 204: 184–184.
Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK. Significant reduction in the incidence of genital warts in young men 5 years into the danish human papillomavirus vaccination program for girls and women. Sex. Transm Dis. 2016; 43(4): 238–242.
[Implementation of health policy programmes by local self-government units, Department of Health], Supreme Audit Office, Warsaw 2016,, access: 28 July 2018. Polish.
[Act of 22 July 2014 on amendment to the act on healthcare services public from public funds and amendment to other selected laws] (Journal of Laws of 2014, item 1138). Polish.
[Act of 29 September 2017 on amendment to the act on healthcare services public from public funds and amendment to other selected laws] (Journal of Laws of 2017, item 2110). Polish.